Company Profile
RemeGen Co., Ltd., a biopharmaceutical company, discovers develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.
The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF).
Its portfolio also includes RC88, an antibody-drug conjugate (ADC) that targets mesothelin, RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF, RC278, an ADC drug for the treatment of multiple solid tumors, and RC288, a dual-antibody ADC drug for the treatment of various tumors. Founded in 2008, the company is headquartered in Yantai, the People's Republic of China.